WO2009086126A3 - Natriuretic polypeptides - Google Patents

Natriuretic polypeptides Download PDF

Info

Publication number
WO2009086126A3
WO2009086126A3 PCT/US2008/087714 US2008087714W WO2009086126A3 WO 2009086126 A3 WO2009086126 A3 WO 2009086126A3 US 2008087714 W US2008087714 W US 2008087714W WO 2009086126 A3 WO2009086126 A3 WO 2009086126A3
Authority
WO
WIPO (PCT)
Prior art keywords
natriuretic
polypeptides
document
natriuretic polypeptides
activities
Prior art date
Application number
PCT/US2008/087714
Other languages
French (fr)
Other versions
WO2009086126A2 (en
Inventor
John C. Burnett, Jr.
Candace Y.W. Lee
Original Assignee
Mayo Foundation For Medical Education And Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation For Medical Education And Research filed Critical Mayo Foundation For Medical Education And Research
Publication of WO2009086126A2 publication Critical patent/WO2009086126A2/en
Publication of WO2009086126A3 publication Critical patent/WO2009086126A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This document provides natriuretic polypeptides. For example, this document provides polypeptides having a natriuretic activity. In some cases, a polypeptide provided herein can have natriuretic activities without lowering blood pressure. This document also provides methods and materials for inducing natriuretic activities within a mammal.
PCT/US2008/087714 2007-12-21 2008-12-19 Natriuretic polypeptides WO2009086126A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1590307P 2007-12-21 2007-12-21
US61/015,903 2007-12-21

Publications (2)

Publication Number Publication Date
WO2009086126A2 WO2009086126A2 (en) 2009-07-09
WO2009086126A3 true WO2009086126A3 (en) 2009-09-17

Family

ID=40825039

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/087714 WO2009086126A2 (en) 2007-12-21 2008-12-19 Natriuretic polypeptides

Country Status (1)

Country Link
WO (1) WO2009086126A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1759001E (en) 2004-04-21 2011-07-12 Enobia Pharma Inc Bone delivery conjugates and method of using same to target proteins to bone
EP1865976B1 (en) 2005-04-07 2012-05-23 Cardiopep Pharma GmbH Use of natriuretic peptide for treating heart failure
US20120108514A1 (en) 2009-07-09 2012-05-03 University Of Iowa Research Foundation Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
WO2012013597A1 (en) * 2010-07-28 2012-02-02 Justus-Liebig-Universität Giessen Substances and the use thereof for influencing natriuretic peptide receptors
JP6055779B2 (en) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド Composition comprising natriuretic peptide and method of use thereof
JP2014525439A (en) 2011-08-30 2014-09-29 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Natriuretic polypeptide
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
SG11201505492XA (en) * 2013-01-25 2015-08-28 Cardiorentis Ltd A natriuretic peptide, a diuretic peptide or a vaso dilatory peptide for use in methods of treating cardiovascular indications
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
EP3226891A1 (en) 2014-12-05 2017-10-11 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
JP6868561B2 (en) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド How to treat subjects with alkaline phosphatase deficiency
KR102644116B1 (en) 2015-08-17 2024-03-05 알렉시온 파마슈티칼스, 인코포레이티드 Preparation of alkaline phosphatase
JP6868617B2 (en) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド Identifying effective dosing regimens for tissue-nonspecific alkaline phosphatase (TNSALP) enzyme replacement therapy for hypophosphataseemia
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
JP2019513711A (en) 2016-04-01 2019-05-30 アレクシオン ファーマシューティカルズ， インコーポレイテッド Treating muscle weakness with alkaline phosphatase
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289A4 (en) 2016-08-18 2020-05-06 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
CN110719786A (en) 2017-03-31 2020-01-21 阿雷克森制药公司 Methods for treating Hypophosphatasia (HPP) in adults and adolescents
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434133A (en) * 1991-01-31 1995-07-18 Suntory Limited CNP analog peptides and their use
US6818619B2 (en) * 1999-12-17 2004-11-16 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
US6828107B2 (en) * 1997-09-11 2004-12-07 Shionogi & Co., Ltd. Immunoassay method for BNP
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434133A (en) * 1991-01-31 1995-07-18 Suntory Limited CNP analog peptides and their use
US6828107B2 (en) * 1997-09-11 2004-12-07 Shionogi & Co., Ltd. Immunoassay method for BNP
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6818619B2 (en) * 1999-12-17 2004-11-16 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides

Also Published As

Publication number Publication date
WO2009086126A2 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
WO2009086126A3 (en) Natriuretic polypeptides
WO2010048308A3 (en) Natriuretic polypeptides
WO2008031045A3 (en) Aquaretic and natriuretic polypeptides lacking vasodilatory activity
EP2765139A3 (en) Natriuretic polypeptides
WO2010002583A3 (en) Natriuretic polypeptides with unique pharmacologic profiles
IL196931A (en) Diuretic and natriuretic polypeptides lacking the blood pressure lowering property and uses thereof
WO2006105338A3 (en) Fc VARIANTS WITH OPTIMIZED PROPERTIES
EP1951166B8 (en) Transapical heart valve delivery system
EP1912667A4 (en) Concentrated protein lyophilates, methods, and uses
WO2007073484A3 (en) Methods and systems for conducting research operations
EP1865888A4 (en) Devices, systems, and methods for reshaping a heart valve annulus
WO2005074546A3 (en) Modified human growth hormone polypeptides and their uses
WO2006069220A3 (en) Modified human growth hormone
EP2214700A4 (en) Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses
WO2009024859A3 (en) Stent-valves for valve replacement and associated methods and systems for surgery
IL183405A0 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
IL188841A0 (en) Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis
EP1906884A4 (en) Methods and systems for cardiac valve delivery
MX272145B (en) Composite nanofiber materials and methods for making same.
IL182885A0 (en) System, in particular, fire-fighting system with valves
EP1781682A4 (en) B7-h5, a costimulatory polypeptide
WO2008098936A3 (en) Valve assembly
IL207648A0 (en) Polypeptide having glyoxalase iii activity, polynucleotied encoding the same and uses thereof
WO2008008917A3 (en) Hydroxyapatite particles
IL184076A0 (en) Membrane card and method for the production and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08868068

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08868068

Country of ref document: EP

Kind code of ref document: A2